Psilocybin (magic mushrooms)
What studies of psilocybin (magic mushrooms) found
At a glance, by condition
Long COVID: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty): 5 findings, all C.
5 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Psilocybin (magic mushrooms) might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Psilocybin (magic mushrooms) · Long COVID is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Symptoms
Cognition (brain fog)1 study Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people, or how many isn't reported; not all results were tested against chance.
Studies with no comparison group1 study · 1 g; 2 g; 2 g; 2 g, first dosing session on May 05, 2022; second dosing session 24 days later on May 29th; July dosing session; November 24th (few people)
Cognition (brain fog) improved.
The evidence is very uncertain about the effect of psilocybin (magic mushrooms) on cognition (brain fog) in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people, or how many isn't reported
- Not all results were tested against chance
See the 1 study
-
Long-COVID symptoms improved after MDMA and psilocybin therapy: A case report. (2024)
- People in the study
- —
- Dose
- 1 g; 2 g; 2 g; 2 g, first dosing session on May 05, 2022; second dosing session 24 days later on May 29th; July dosing session; November 24th
- Outcome
- cognitive function
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Pain1 study Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people, or how many isn't reported; not all results were tested against chance.
Studies with no comparison group1 study · 1 g; 2 g; 2 g; 2 g, first dosing session on May 05, 2022; second dosing session 24 days later on May 29th; July dosing session; November 24th (few people)
Pain improved.
The evidence is very uncertain about the effect of psilocybin (magic mushrooms) on pain in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people, or how many isn't reported
- Not all results were tested against chance
See the 1 study
-
Long-COVID symptoms improved after MDMA and psilocybin therapy: A case report. (2024)
- People in the study
- —
- Dose
- 1 g; 2 g; 2 g; 2 g, first dosing session on May 05, 2022; second dosing session 24 days later on May 29th; July dosing session; November 24th
- Outcome
- unique headache
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Sleep1 study Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people, or how many isn't reported; not all results were tested against chance.
Studies with no comparison group1 study · 1 g; 2 g; 2 g; 2 g, first dosing session on May 05, 2022; second dosing session 24 days later on May 29th; July dosing session; November 24th (few people)
Sleep improved.
The evidence is very uncertain about the effect of psilocybin (magic mushrooms) on sleep in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people, or how many isn't reported
- Not all results were tested against chance
See the 1 study
-
Long-COVID symptoms improved after MDMA and psilocybin therapy: A case report. (2024)
- People in the study
- —
- Dose
- 1 g; 2 g; 2 g; 2 g, first dosing session on May 05, 2022; second dosing session 24 days later on May 29th; July dosing session; November 24th
- Outcome
- insomnia
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Daily life and health overall
Overall symptoms2 studies · 110 people took psilocybin (magic mushrooms) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance.
Studies with no comparison group2 studies · 110 people with results
Overall symptoms improved.
The evidence is very uncertain about the effect of psilocybin (magic mushrooms) on overall symptoms in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Not all results were tested against chance
See the 2 studies
-
- People in the study
- 110 in the study
- Dose
- self-described microdose vs. not: "Most individuals reported microdosing psilocybin (51.8%, N = 57), and of those 57 individuals, 16 (14.5%) also described taking doses that resulted in a psychedelic experience (macrodose).", repeat dosing vs single dosing: table row "Repeat Dosing Reported" — "Yes 56 50.9"
- Outcome
- Any Improvement in Any Symptoms
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
-
Long-COVID symptoms improved after MDMA and psilocybin therapy: A case report. (2024)
- People in the study
- —
- Dose
- 1 g; 2 g; 2 g; 2 g, first dosing session on May 05, 2022; second dosing session 24 days later on May 29th; July dosing session; November 24th
- Outcome
- symptoms abated to 90% relief of symptoms
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Daily functioning1 study Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people, or how many isn't reported; not all results were tested against chance.
Studies with no comparison group1 study · 1 g; 2 g; 2 g; 2 g, first dosing session on May 05, 2022; second dosing session 24 days later on May 29th; July dosing session; November 24th (few people)
Daily functioning improved.
The evidence is very uncertain about the effect of psilocybin (magic mushrooms) on daily functioning in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people, or how many isn't reported
- Not all results were tested against chance
See the 1 study
-
Long-COVID symptoms improved after MDMA and psilocybin therapy: A case report. (2024)
- People in the study
- —
- Dose
- 1 g; 2 g; 2 g; 2 g, first dosing session on May 05, 2022; second dosing session 24 days later on May 29th; July dosing session; November 24th
- Outcome
- return to work
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Side effects
Side effects studies reported3 kinds
| Side effect | Studies that reported it |
|---|---|
| Anxiety or irritability | 1 study |
| Nausea or stomach upset | 1 study |
| Worse symptoms or a flare | 1 study |
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
1 mg at the start
- 2Top dose
Most often 1 mg (1 of 1 studies)
Doses across 1 study
1 to 1 mg.
Each study’s dose, as printed
- 1 mg or 2 mg of combined psilocybin and psilocin every third day; 40 mg for Case 1 and 60 mg for Case 2, 8-week outpatient microdosing and psychotherapy phase; therapeutic-dose session during week 9 Psilocybin-containing mushroom-assisted psychotherapy is associated with sustained psychological and somatic improvements: two case studies from Jamaica. (2026)
All papers
- Therapeutic Potential of Psilocybin for Treating Neuropsychiatric Long COVID Symptoms: A Reddit Investigation.2026 · no comparison group · 110 in the study
Summary
This study examined publicly available Reddit posts from r/LongCovid and r/covidlonghaulers, searched on January 10th, 2024, to explore self-reported psilocybin use for neuropsychiatric long COVID symptoms. It included 110 unique individuals whose posts described long COVID neuropsychiatric symptoms, psilocybin use, and the perceived effect on symptoms. There was no comparison group; psilocybin was self-reported, and duration of use was not reported. Posts were manually coded for perceived improvement, worsening, and duration of effects. Of 110 individuals, 86 (78.2%) reported some level of improvement in at least one long COVID symptom; of those 86, 18 (20.9%) reported improvement in all symptoms and 20 (23.3%) reported symptoms returned to pre-COVID-19 baseline or fully resolved. Of the 86 who reported improvement, 67 (77.9%) reported improvement persisting after the acute psychedelic experience; of these 67, 21 (31.3%) reported effects eventually waned, and 5 (5.8%) reported improvement only during the experience. Of 110 individuals, 13 (11.8%) reported any worsening; of those 13, 3 (23.1%) reported worsening only during the experience and 3 (23.1%) reported worsening lasting beyond it. The authors state limitations including reliance on unverified self-report and Reddit data.
- Long-COVID symptoms improved after MDMA and psilocybin therapy: A case report.2024 · case report
Summary
This case report describes a 41-year-old female with Long-COVID syndrome after contracting COVID-19 in February 2022. She self-medicated with psilocybin and MDMA under a therapist-recommended protocol. The first dosing session, on May 05, 2022, was 1 g of dried golden teacher psilocybin cubensis mushrooms; she reported a 20% improvement in depression, fatigue, joint pains, and headache for 7 days. The second session, 24 days later, was MDMA 125 mg followed 1 h later by 2 g of mushrooms in tea and 1 h later by a second 2 g of mushrooms in tea. After this session the patient reported significant improvement in post-COVID symptoms; headache frequency reduced to approximately once per week from a May 2022 baseline of 5 per week, duration decreased to less than 2–4 h per attack from a typical 8–12 h, and she rated symptom improvement approximately 80%. After another 2 g dose, symptoms abated to 90% relief. She later had an early November relapse, then after 2 g on November 24th reported complete resolution and returned to work 3 days later. Harms included chills and shivering with a sensation of being cold while “coming up” and transient nausea and emesis 40 min after ingestion. No comparison group was studied.
- Psilocybin-containing mushroom-assisted psychotherapy is associated with sustained psychological and somatic improvements: two case studies from Jamaica.2026 · combination: given with other treatments · 2 in the study
Summary
This paper reports two case studies from a private psychiatry practice in Jamaica, examining psychological and somatic changes associated with the De La Haye Psilocybin Treatment Protocol (DPTP). Two patients underwent an 8-week outpatient phase of psilocybin-containing mushroom biomass microdoses (1 mg or 2 mg combined psilocybin and psilocin every third day) with psychotherapy every 2 weeks, followed by an optional week 9 therapeutic-dose session (40 mg for Case 1; 60 mg for Case 2). Case 1 presented with depression, anxiety, PTSD and chronic musculoskeletal pain; Case 2 presented with complex PTSD and Long COVID-19 anosmia and ageusia. Both received psychotherapy and an integration session. Follow-up was approximately two months after the therapeutic session; MEQ-30 scores were 99 and 119. Patient reports described improved psychological well-being, reduced shame and social anxiety, reduced shoulder and ankle pain, resolution of diffuse body aches, and an 80-90% return of smell. No serious adverse events were reported, and acute psychedelic effects were not classified as adverse events. The authors state the design lacks a control or comparison group, that validated baseline and follow-up measures were not collected, and that spontaneous improvement cannot be excluded.